Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Authors
Keywords
-
Journal
EUROPEAN HEART JOURNAL
Volume 43, Issue 31, Pages 2931-2945
Publisher
Oxford University Press (OUP)
Online
2022-06-18
DOI
10.1093/eurheartj/ehac299
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study
- (2022) Peter Rossing et al. DIABETES CARE
- Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
- (2022) Gerasimos Filippatos et al. EUROPEAN JOURNAL OF HEART FAILURE
- Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone
- (2022) Nicholas Chiu et al. Journal of the American Heart Association
- Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms
- (2022) Johann Bauersachs et al. Kidney International Supplements
- Antagonistic effects of finerenone and spironolactone on the aldosterone‐regulated transcriptome of human kidney cells
- (2021) Florian Le Billan et al. FASEB JOURNAL
- Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats
- (2021) Asadur Rahman et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
- (2021) George Bakris et al. HYPERTENSION
- Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2021) Gerasimos Filippatos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
- (2021) Peter Kolkhof et al. AMERICAN JOURNAL OF NEPHROLOGY
- Finerenone: First Approval
- (2021) James E. Frampton DRUGS
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change
- (2021) Sudeep R. Aryal et al. Journal of the American Heart Association
- The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
- (2021) Frédéric Jaisser et al. Frontiers in Pharmacology
- Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
- (2021) Gerasimos Filippatos et al. CIRCULATION
- Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
- (2021) Peter Rossing et al. DIABETES OBESITY & METABOLISM
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
- (2021) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
- (2021) Javed Butler et al. EUROPEAN JOURNAL OF HEART FAILURE
- Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
- (2021) Rajiv Agarwal et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
- (2021) Peter Kolkhof et al. PHARMACOLOGICAL RESEARCH
- Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
- (2021) Peter Rossing et al. Kidney International Reports
- Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial
- (2020) Pierpaolo Pellicori et al. EUROPEAN JOURNAL OF HEART FAILURE
- Structural determinants of activation of the mineralocorticoid receptor: an evolutionary perspective
- (2020) Peter J. Fuller et al. JOURNAL OF HUMAN HYPERTENSION
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice
- (2019) Abdus Sattar Bhuiyan et al. HYPERTENSION RESEARCH
- The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone
- (2019) Krister Bamberg et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Esaxerenone: First Global Approval
- (2019) Sean Duggan DRUGS
- Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association
- (2019) Janani Rangaswami et al. CIRCULATION
- Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial
- (2019) Joachim Alexandre et al. AMERICAN HEART JOURNAL
- Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial
- (2019) Heerajnarain Bulluck et al. AMERICAN HEART JOURNAL
- A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients
- (2019) Fabian Hammer et al. KIDNEY INTERNATIONAL
- Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
- (2019) Andrew Whittaker et al. CTS-Clinical and Translational Science
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator
- (2018) Fredrik Erlandsson et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction
- (2018) Marianne Lachaux et al. DIABETES OBESITY & METABOLISM
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion
- (2018) Krister Bamberg et al. PLoS One
- Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
- (2018) Bryan Williams et al. Lancet Diabetes & Endocrinology
- Cardiorenal Syndrome Revisited
- (2018) Faiez Zannad et al. CIRCULATION
- Macrophage Mineralocorticoid Receptor Is a Pleiotropic Modulator of Myocardial Infarct Healing
- (2018) Daniela Fraccarollo et al. HYPERTENSION
- Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial
- (2018) David M. Charytan et al. KIDNEY INTERNATIONAL
- Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
- (2018) Raquel González-Blázquez et al. Frontiers in Pharmacology
- Canrenone on cardiovascular mortality in congestive heart failure
- (2018) Giuseppe Derosa et al. PHARMACOLOGICAL RESEARCH
- Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF
- (2017) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease
- (2017) Evan B. Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?
- (2016) Hermann Haller et al. CURRENT HYPERTENSION REPORTS
- Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences
- (2016) Jun Yang et al. CURRENT OPINION IN PHARMACOLOGY
- Cardiac Tissue Injury and Remodeling Is Dependent Upon MR Regulation of Activation Pathways in Cardiac Tissue Macrophages
- (2016) Jimmy Z. Shen et al. ENDOCRINOLOGY
- Finerenone in heart failure: walking a fine line
- (2016) Matthias Naegele et al. EUROPEAN HEART JOURNAL
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis
- (2016) RenJie Lu et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
- (2016) Jana Grune et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Mineralocorticoid regulation of cell function: the role of rapid signalling and gene transcription pathways
- (2016) Gregory S Y Ong et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Early Aldosterone Blockade in Acute Myocardial Infarction
- (2016) Farzin Beygui et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Adult nephron-specific MR-deficient mice develop a severe renal PHA-1 phenotype
- (2016) Jérémie Canonica et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
- (2015) Peter Bramlage et al. EUROPEAN JOURNAL OF HEART FAILURE
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Cardiomyocyte Mineralocorticoid Receptor Activation Impairs Acute Cardiac Functional Recovery After Ischemic InsultNovelty and Significance
- (2015) Laura A. Bienvenu et al. HYPERTENSION
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Direct and Indirect Mineralocorticoid Effects Determine Distal Salt Transport
- (2015) A. S. Terker et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
- (2015) Bryan Williams et al. LANCET
- Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study
- (2014) G. Montalescot et al. EUROPEAN HEART JOURNAL
- Identification and characterization of a ligand-selective mineralocorticoid receptor coactivator
- (2014) Fraser M. Rogerson et al. FASEB JOURNAL
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy
- (2014) A Gupta et al. JOURNAL OF HUMAN HYPERTENSION
- Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease
- (2014) L. L. Huang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis
- (2013) Nancy J. Brown Nature Reviews Nephrology
- PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
- (2013) Stephen Orena et al. Frontiers in Pharmacology
- Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
- (2012) Lars Bärfacker et al. ChemMedChem
- The Ubiquitous Mineralocorticoid Receptor: Clinical Implications
- (2012) Urseline A. Hawkins et al. CURRENT HYPERTENSION REPORTS
- Cardiomyocyte Mineralocorticoid Receptors Are Essential for Deoxycorticosterone/Salt-Mediated Inflammation and Cardiac Fibrosis
- (2012) Amanda J. Rickard et al. HYPERTENSION
- Deletion of Cardiomyocyte Mineralocorticoid Receptor Ameliorates Adverse Remodeling After Myocardial Infarction
- (2011) Daniela Fraccarollo et al. CIRCULATION
- Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction
- (2011) S. Kasama et al. HEART
- Mechanisms of ligand specificity of the mineralocorticoid receptor
- (2011) Peter J Fuller et al. JOURNAL OF ENDOCRINOLOGY
- Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
- (2011) Peter Kolkhof et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice
- (2010) Michael G. Usher et al. JOURNAL OF CLINICAL INVESTIGATION
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloid-Specific Deletion of the Mineralocorticoid Receptor Reduces Infarct Volume and Alters Inflammation During Cerebral Ischemia
- (2010) Ryan A. Frieler et al. STROKE
- Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results
- (2009) Alessandro Boccanelli et al. EUROPEAN JOURNAL OF HEART FAILURE
- Deletion of Mineralocorticoid Receptors From Macrophages Protects Against Deoxycorticosterone/Salt-Induced Cardiac Fibrosis and Increased Blood Pressure
- (2009) Amanda J. Rickard et al. HYPERTENSION
- Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease
- (2009) Nicola C. Edwards et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A Comparison of the Aldosterone-blocking Agents Eplerenone and Spironolactone
- (2008) Allan Struthers et al. CLINICAL CARDIOLOGY
- Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone
- (2008) P. Mulder et al. EUROPEAN HEART JOURNAL
- Cardiorenal Syndrome
- (2008) Claudio Ronco et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist
- (2007) Frances McManus et al. Nature clinical practice. Endocrinology & metabolism
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More